At week 48 , 217 ( 90 % ) patients receiving dolutegravir and 200 ( 83 % ) patients receiving darunavir plus ritonavir had HIV-1 RNA of less than 50 copies per mL ( adjusted difference 71 % , 95 % CI 09-132 ) , non-inferiority and on pre-specified secondary analysis dolutegravir was superior ( p = 0025 ) .